Duffy Antigen Status, Hydroxyurea Dosing, and Disease Severity in Children and Young Adults With Sickle Cell Disease
Pediatric Blood & Cancer · 2026
DOI: 10.1002/1545-5017.70577 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Alison Celello und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Hydroxyurea, Anemia, Sickle Cell, Duffy Blood-Group System, Antisickling Agents. Die Arbeit nennt 13 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Most patients with sickle cell disease (SCD) also have the Duffy null red blood cell phenotype, often leading to lower absolute neutrophil counts (ANC). Hydroxyurea titration in SCD is largely driven by ANC. Hydroxyurea maximum tolerated dose (MTD) attainment, MTD dosage, and metrics of SCD severity based on both MTD attainment and Duffy antigen status were analyzed in pediatric and young adult patients. Rates of vasoocclusive episodes and emergency room visits for complications of SCD were increased in the total cohort of Duffy antigen positive patients and in Duffy antigen positive patients who attained MTD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.
ORCID-Profile: Alison Celello, Christopher McKinney
Zitieren
APA
Celello, A., & McKinney, C. (2026). Duffy Antigen Status, Hydroxyurea Dosing, and Disease Severity in Children and Young Adults With Sickle Cell Disease. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70577
Vancouver
Celello A, McKinney C. Duffy Antigen Status, Hydroxyurea Dosing, and Disease Severity in Children and Young Adults With Sickle Cell Disease. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70577
BibTeX
@article{Celello2026,
author = {Celello, Alison and McKinney, Christopher},
title = {Duffy Antigen Status, Hydroxyurea Dosing, and Disease Severity in Children and Young Adults With Sickle Cell Disease},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70577}
}
EUVIMED